Related Experiment Video
Updated: Dec 30, 2025

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant
Joanna Achinger-Kawecka1,2, Fatima Valdes-Mora1,2, Phuc-Loi Luu1,2
1Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Abstract:
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resistance. We observe that loss of 3D chromatin interactions often occurs coincidently with hypermethylation and loss of ER binding. Alterations in active A and inactive B chromosomal compartments are also associated with decreased ER binding and atypical interactions and gene expression. Together, our results suggest that 3D epigenome remodelling is a key mechanism underlying endocrine resistance in ER+ breast cancer.
Insights
3D chromatin interactions change in endocrine-resistant estrogen receptor-positive breast cancer. This 3D epigenome remodeling, involving altered enhancers, promoters, and gene expression, is a key mechanism driving resistance.
Area of Science:
- Genomics
- Epigenetics
- Cancer Biology
Background:
- Endocrine therapy resistance is a major challenge in estrogen receptor-positive (ER+) breast cancer.
- The molecular mechanisms driving this resistance are not fully understood.
Purpose of the Study:
- To investigate the role of 3D chromatin interactions in the development of endocrine resistance in ER+ breast cancer.
Main Methods:
- Analysis of 3D chromatin interactions within and between topologically associating domains (TADs) in endocrine-resistant ER+ breast cancer cells.
- Identification of genetic variants at CTCF-bound anchors and their association with differential interactions.
- Assessment of enhancer and promoter activity, ER binding sites, and gene expression alterations.
Main Results:
- Significant changes in 3D chromatin interactions were observed in endocrine-resistant cells.
- Differential interactions were enriched for resistance-associated genetic variants at CTCF-bound anchors.
- Ectopic interactions correlated with altered ER-regulated gene expression, suggesting dynamic pathway remodeling.
- Loss of interactions coincided with hypermethylation and reduced ER binding.
- Alterations in chromosomal compartments (A and B) were linked to decreased ER binding and atypical gene expression.
Conclusions:
- 3D epigenome remodeling, including changes in chromatin interactions and chromosomal compartments, is a critical mechanism underlying endocrine resistance in ER+ breast cancer.
- These epigenetic alterations impact ER binding, enhancer/promoter activity, and gene expression, contributing to therapeutic failure.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Inheritance of Chromatin Structures
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Introduction to Nuclear Reprogramming

